Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer

• Published in: Radiation oncology (London, England) England), 2023-09, Vol.18 (1), p.1-154, Article 154
• Main Authors: Navarro-Domenech, Inmaculada, Arulanantham, Shinthujah, Liu, Zhihui Amy, Tjong, Michael, Kong, Vickie, Malkov, Victor, Tadic, Tony, Fleshner, Neil, Kulkarni, Girish, Zlotta, Alexandre R, Catton, Charles, Berlin, Alejandro, Sridhar, Srikala, Jiang, Di (Maria), Chung, Peter, Raman, Srinivas
• Format: Article
• Language: English
• Subjects: Bladder; Bladder cancer; Cancer; Cancer patients; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Disease control; Dose-painted; Dosimetry; Endoscopy; Hydronephrosis; Injection; Invasiveness; Lipiodol; Medical imaging; Medical prognosis; Metastases; Metastasis; Methyl isobutyl carbinol; Muscles; Patient outcomes; Patients; Pelvis; Radiation dosage; Radiation therapy; Radiotherapy; Survival; Toxicity; Tri-modal therapy; Tumors; Urological surgery
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/s13014-023-02338-w

Purpose/Objective Definitive radiotherapy (RT) is an alternative to radical cystectomy for select patients with muscle invasive bladder cancer (MIBC); however, there is limited data on dose-painted RT approaches. We report the clinical and dosimetric outcomes of a cohort of MIBC patients treated with dose-painted RT. Material/Methods This was a single institution retrospective study of cT2-4N0M0 MIBC patients treated with external beam radiotherapy (EBRT) to the bladder, and sequential or concomitant boost to the tumor bed. The target delineation was guided by either intravesical injection of Lipiodol or through fusion of the pre-treatment imaging. The majority were treated with daily image-guidance. Kaplan-Meier was used to characterize overall survival (OS) and progression-free survival (PFS). Cumulative incidence function (CIF) was used to estimate local (intravesical) recurrence (LR), regional recurrence (RR) and distant metastasis (DM). Univariable and multivariable cause-specific hazard model was used to assess factors associated with LR and OS. Results 117 patients were analyzed. The median age was 73 years (range 43, 95). The median EQD2 to the boost volume was 66 Gy (range 52.1, 70). Lipiodol injection was used in 64 patients (55%), all treated with IMRT/VMAT. 95 (81%) received concurrent chemotherapy, of whom, 44 (38%) received neoadjuvant chemotherapy. The median follow-up was 37 months (IQR 16.2, 83.3). At 5-year, OS and PFS were 79% (95% CI 70.5-89.2) and 46% (95% CI 36.5-57.5). Forty-five patients had bladder relapse, of which 30 patients (67%) were at site of the tumor bed. Nine patients underwent salvage-cystectomy. Late high-grade (G3-G4) genitourinary and gastrointestinal toxicity were 3% and 1%. Conclusion Partial boost RT in MIBC is associated with good local disease control and high rates of cystectomy free survival. We observed a pattern of predominantly LR in the tumor bed, supporting the use of a dose-painted approach/de-escalation strategy to the uninvolved bladder. Prospective trials are required to compare oncological and toxicity outcomes between dose-painted and homogeneous bladder RT techniques. Keywords: Bladder cancer, Radiotherapy, Dose-painted, Lipiodol, Tri-modal therapy